News | Heart Valve Technology | July 26, 2018

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes

Slow progression of disease may mask symptoms until damage cannot be fully repaired

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes

July 26, 2018 — The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many patients do not undergo surgical intervention until it is too late to completely reverse damage caused by mitral valve disease. The study is posted online in The Annals of Thoracic Surgery.

“This study shows that a significant number of patients are still referred for mitral valve surgery later than they should be,” said James S. Gammie, M.D., from the University of Maryland School of Medicine in Baltimore. “In these cases, the malfunctioning mitral valve has caused significant damage to the heart and/or lungs, and while an operation can be performed, long-term outcomes will be compromised, to some extent.”

Gammie, Vinay Badhwar, M.D., from West Virginia University in Morgantown, W. Va., and colleagues analyzed data from The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) in order to determine trends related to current mitral valve operations in North America. The ACSD contains more than 6.5 million cardiac surgery procedure records, representing more than 90 percent of all adult cardiac surgery hospitals across the United States and Canada.

The researchers identified 87,214 patients at 1,125 centers who had isolated primary mitral valve operations from July 2011 to September 2016. The average age of patients in this group was 64 years; half were female. During the study period, the number of mitral valve operations performed per year increased by 24 percent, from 14,442 in 2011 to 17,907 in 2016. There was a 44 percent increase in primary mitral operations performed for degenerative disease, the most common form of mitral valve disease in the United States.

“This suggests that the mitral valve disease may have reached a chronic stage prior to referral for operation, which means that heart and lung damage may not be fully reversible,” explained Badhwar. “In these patients, their symptoms may improve after surgery, but their life expectancy may be reduced.”

The mitral valve is the inflow valve between the lungs and the left ventricle, the main pumping chamber of the heart. This valve allows blood to enter the heart from the lungs when the heart muscle is relaxing and also prevents backflow of blood when the heart squeezes. Mitral valve diseases include mitral regurgitation (leaking) and mitral stenosis (narrowing), which may cause fatigue and shortness of breath.

“Once the leakage is severe, heart damage may result, thus mitral valve operation is recommended,” said Badhwar. “The preferred operation is mitral repair, whenever possible. If performed in a timely manner, the patient’s heart function and life expectancy may return to normal.”

In this study, the data showed that the overall repair rate was 65.6 percent (57,244) and the replacement rate was 34.4 percent (29,970). Overall operative mortality was 2 percent (1,762).

“We found that the number of operations performed for mitral valve disease is growing faster than any other category of heart operation and that the results were excellent with low risks of death and complications,” said Gammie.

The researchers also revealed that while the prevalence of mitral valve disease and the number of mitral valve operations performed per year are increasing, overall aortic valve operations were performed 1.6 times more commonly than mitral valve operations during the study period.

“This may suggest important under-referral and under-treatment of mitral valve disease, which may be related to the slower progression of signs and symptoms of mitral compared to aortic disease, as well as potential lack of adherence to guidelines for intervention,” said Gammie. “So although contemporary outcomes are excellent, there remains an important and substantial opportunity to improve results for patients with mitral valve disease by following established guidelines and encouraging earlier referral for operation.”

For more information: www.annalsthoracicsurgery.org

Reference

Gammie J.S., Chikwe J., Badhwar V., et al. "Isolated Mitral Valve Surgery: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis." Annals of Thoracic Surgery, published online July 18, 2018. https://doi.org/10.1016/j.athoracsur.2018.03.086

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init